Holen Sie sich die Stockscreener-App
5.04
5.44%
0.26
Handel nachbörslich:
5.01
-0.03
-0.60%
Cellectar Biosciences Inc Aktie (CLRB) Neueste Nachrichten
What makes Cellectar Biosciences Inc. stock price move sharplySafety First Trading Signals - Newser
All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy - Yahoo Finance
Why Cellectar Biosciences Inc. stock attracts strong analyst attentionFree Stock Market Return Analysis - Newser
How Cellectar Biosciences Inc. stock performs during market volatilityGrowth Stock Monitor - Newser
Waldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements | DelveInsight - GlobeNewswire Inc.
Sequoia Financial Advisors LLC Purchases 188,760 Shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar Biosciences shares rise 3.59% premarket after closing $6.9 million public offering. - AInvest
Cellectar Biosciences Closes $6.9 Million Public Offering - MarketScreener
Cellectar Biosciences, Inc. Completes $6.9 Million Public Offering to Advance Cancer Treatment Development - Nasdaq
Cellectar Biosciences Announces Closing of $6.9 Million - GlobeNewswire
Cellectar Secures $6.9M Funding: Healthcare Funds Back New Breast Cancer Drug Development - Stock Titan
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering | CLRB Stock News - GuruFocus
Cellectar Biosciences prices $6 million public offering - Investing.com
Cellectar Biosciences, Inc. Announces Pricing of Underwritten Public Offering for Approximately $6 Million - Quiver Quantitative
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering - Yahoo Finance
Cellectar Biosciences (NASDAQ:CLRB) Rating Increased to Sell at Wall Street Zen - Defense World
Cellectar Biosciences, Inc. and Nusano Enter into Multi-Isotope Supply Agreement - MarketScreener
Cellectar Biosciences provides update on clinical programs and preclinical data - Investing.com
Cellectar and Nusano sign multi-year radioisotope supply agreement By Investing.com - Investing.com India
Breakthrough TNBC Treatment Advances: FDA to Review Novel Radiopharmaceutical Trial Protocol - Stock Titan
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split - The Manila Times
Cellectar Biosciences announces one-for-thirty reverse stock split - MarketScreener
Cellectar Biosciences (CLRB) Announces One-for-Thirty Reverse St - GuruFocus
Cellectar Biosciences announces 1:30 reverse stock split - Investing.com
Cellectar Biosciences (CLRB) Announces Reverse Stock Split | CLR - GuruFocus
Cellectar Biosciences Reports 1-for-30 Reverse Stock Split, Effective June 24 - marketscreener.com
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split | CLRB Stock News - GuruFocus
Cellectar Biosciences, Inc. Announces One-for-Thirty Reverse Stock Split Effective June 24, 2025 - Nasdaq
Roth Capital Issues Positive Estimate for CLRB Earnings - Defense World
Cellectar Biosciences Approves Reverse Stock Split Proposal - TipRanks
Cellectar Biosciences (CLRB) Reports Promising Phase 1 Trial Res - GuruFocus
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 - GlobeNewswire
Cellectar reports improved survival in pediatric brain tumor trial By Investing.com - Investing.com India
Cellectar reports improved survival in pediatric brain tumor trial - Investing.com
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma - The Manila Times
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma | CLRB Stock News - GuruFocus
Breakthrough: New Drug Doubles Survival Time in Aggressive Childhood Brain Cancer Trial - Stock Titan
Squarepoint Ops LLC Makes New Investment in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar Biosciences announces $2.5 million stock sale By Investing.com - Investing.com India
Cellectar Biosciences Enters into Common Stock Agreements to Rai - GuruFocus
Cellectar Biosciences Expects to Raise $2.5 Million via Stock Sale, Warrant Exercise - marketscreener.com
Cellectar Biosciences (CLRB) Secures $2.5 Million from Stock Sal - GuruFocus
Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year? - Yahoo Finance
Cellectar Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Cellectar Biosciences (CLRB) Secures $2.5M Through Stock Sale Agreements | CLRB Stock News - GuruFocus
Cellectar Biosciences announces $2.5 million stock sale - Investing.com Australia
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules | CLRB Stock News - GuruFocus
Cellectar Biosciences Enters into Common Stock Agreements - GlobeNewswire
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules - Yahoo Finance
FDA Designation Sparks Rally For This Biotech - The Globe and Mail
Cellectar Biosciences stock soars on FDA breakthrough designation - Investing.com Australia
Cellectar Biosciences stock soars on FDA breakthrough designation By Investing.com - Investing.com Canada
3.40%
2.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):